Medicine and Dentistry
Radioembolization
100%
Yttrium 90
98%
Neoplasm
66%
Hepatocellular Carcinoma
54%
Magnetic Resonance Imaging
45%
Overall Survival
41%
Microsphere
36%
Liver Tumor
36%
Diseases
27%
Liver Metastasis
26%
Breast Cancer
20%
Liver Cancer
19%
Dosimetry
19%
Tumor Model
19%
Segmentectomy
19%
Metastatic Carcinoma
18%
Cancer
17%
Intraarterial Drug Administration
14%
Adverse Event
14%
Transcatheter Arterial Chemoembolization
13%
Cholangiocarcinoma
12%
Lobectomy
12%
Response Evaluation Criteria in Solid Tumors
10%
Positron Emission Tomography-Computed Tomography
9%
Positron Emission Tomography
9%
Infusion
8%
Liver Function
7%
Ex Vivo
7%
Doxorubicin
7%
Metastatic Colorectal Cancer
7%
Cell Migration
7%
Pancreas Cancer
7%
Biological Marker
6%
Shunt Creation
6%
Transjugular Intrahepatic Portosystemic Shunt
6%
Fluorodeoxyglucose F 18
6%
Hyperthermia
6%
Tumor Hypoxia
6%
Volume CT
6%
Irreversible Electroporation
6%
Polyethylene Terephthalate
6%
Superparamagnetic Iron Oxide
6%
Image Guided Biopsy
6%
Systemic Therapy
6%
Female Genital Tract Cancer
6%
Proton Nuclear Magnetic Resonance
6%
Iron Oxide
6%
Biopsy Technique
6%
Pancreas Carcinoma
6%
Carcinoma
6%
Keyphrases
Yttrium-90 Radioembolization
70%
Yttrium-90
56%
Hepatocellular Carcinoma
54%
Radioembolization
47%
Tumor
38%
Overall Survival
28%
Magnetic Resonance Imaging
26%
Rabbit Model
22%
Time to Progression
21%
Liver Tumor
20%
Clinical Translation
19%
Radiation Segmentectomy
19%
Liver
17%
Median Overall Survival
16%
Transcatheter
16%
Rabbit Liver
15%
Dosimetry
14%
Liver Cancer
14%
Transarterial Radioembolization
14%
Chemoembolization
14%
Clinical Toxicity
13%
Natural Killer Cells
12%
Computational Imaging
12%
Liver Model
12%
Radiopaque Microspheres
12%
Breast Cancer Liver Metastases
12%
Radiation Lobectomy
12%
Conventional Transarterial Chemoembolization (cTACE)
11%
Peri-procedural
11%
Tumor Response
11%
Hepatic Malignancy
10%
VX2 Tumor
10%
Chemotherapy
10%
Metastasis
10%
Positron Emission Tomography-computed Tomography (PET-CT)
10%
Response Evaluation Criteria in Solid Tumors (RECIST)
10%
Intra-arterial
10%
Biochemical Toxicity
10%
Imaging Response
10%
Image-guided
9%
Extrahepatic Disease
9%
Breast Cancer
9%
Locoregional Therapy
9%
Confidence Interval
9%
Adverse Events
9%
Transcatheter Intervention
8%
Tumor Size
8%
Dose Effect
8%
Doxorubicin
8%
Median Time
8%